Pacira BioSciences, Inc.

PCRX · Nasdaq · United States

Share price · PCRX

$36.48+13.24 (+56.97%) 3M

close as of 2026-11-16 · 24h delayed · vol 1.8M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PCRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 8 Oct 2026+44.4%
  2. 5 Aug 2026-10.0%
  3. 26 May 2026+4.3%

    Nothing announced by PCRX that day or the session before.

  4. 6 May 2026-4.4%

    Nothing announced by PCRX that day or the session before.

  5. 27 Apr 2026+4.2%

    Nothing announced by PCRX that day or the session before.

  6. 16 Jan 2026-7.2%

    Nothing announced by PCRX that day or the session before.

  7. 15 Jan 2026-7.1%

    Nothing announced by PCRX that day or the session before.

  8. 13 Jan 2026-5.8%

    Nothing announced by PCRX that day or the session before.

  9. 9 Jan 2026-9.6%

    Nothing announced by PCRX that day or the session before.

  10. 2 Jan 2026-5.5%

    Nothing announced by PCRX that day or the session before.

Share of unusual movement by asset

For each asset, the share of PCRX's own-move activity since 3 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—65%
Sessions with no dated event—35%

No dated announcements about its assets since 3 Nov 2025.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Amide Local AnestheticSmall molecule
Acute Pain

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$177M$27M$247M+ $49M short-term inv.—$50M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$192M$30M$206M+ $45M short-term inv.—$57M operating cash flowreport ↗
2026-Q1$177M$28M$144M+ $58M short-term inv.—$26M operating cash flowreport ↗
2025-Q3$180M$26M$148M+ $99M short-term inv.—$61M operating cash flowreport ↗
2025-Q2$181M$28M$300M+ $145M short-term inv.$4.8M$12M operating cash flowreport ↗
2025-Q1$169M$25M$284M+ $210M short-term inv.—$35M operating cash flowreport ↗
2024-Q3$169M$19M$246M+ $208M short-term inv.$143M$54M operating cash flowreport ↗
2024-Q2$178M$20M$247M+ $157M short-term inv.—$53M operating cash flowreport ↗
2024-Q1$167M$18M$184M+ $142M short-term inv.—$49M operating cash flowreport ↗
2023-Q3$164M$21M$99M+ $136M short-term inv.—$44M operating cash flowreport ↗
2023-Q2$169M$19M$87M+ $134M short-term inv.—$44M operating cash flowreport ↗
2023-Q1$160M$17M$36M+ $138M short-term inv.$20M$19M operating cash flowreport ↗
2022-Q3$167M$19M$109M+ $219M short-term inv.$0.7M$43M operating cash flowreport ↗
2022-Q2$169M$26M$122M+ $194M short-term inv.—$30M operating cash flowreport ↗
2022-Q1$158M$22M$227M+ $225M short-term inv.—$31M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$726M$117M$159M+ $80M short-term inv.—$152M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$701M$82M$277M+ $208M short-term inv.$25M$189M operating cash flowreport ↗
2023-FY$675M$76M$153M+ $125M short-term inv.—$155M operating cash flowreport ↗
2022-FY$667M$85M$104M+ $185M short-term inv.—$145M operating cash flowreport ↗
2021-FY$539M$56M$586M+ $71M short-term inv.—$126M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 15 sales ($2.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17SLONIN JONATHAN · Chief Medical OfficerDisposition to issuer216,729.67$36.50$7.9MForm 4
2026-11-17Brege Laura · directorCode U23,715$36.50$866KForm 4
2026-11-17RIKER LAUREN · Senior Vice President, FinanceCode U6,881.242$36.50$251KForm 4
2026-11-17WIGGANS THOMAS G · directorDisposition to issuer (derivative)32,675——Form 4
2026-11-17BIGAL MARCELO · directorCode U11,393$36.50$416KForm 4
2026-11-17Froimson Mark · directorCode U20,136$36.50$735KForm 4
2026-11-17Cross Shawn · Chief Financial OfficerCode U9,210$36.50$336KForm 4
2026-11-17CHRISTIE CHRISTOPHER · directorCode U16,654$36.50$608KForm 4